CTIS2024-513904-33-00进行中（未招募）1 期
ongterm Follow-up of Subjects with Cerebral Adrenoleukodystrophy Who Were Treated with Lenti-D Drug Product - LTF-304
Bluebird Bio Inc.0 个研究点目标入组 64 人开始时间: 2024年7月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 17（—）
- 性别
- Male
入选标准
- •Provision of written informed consent for this study by the subject or subject's parent(s)/ legal guardian(s) and written informed assent by subject, if applicable, Have received Lenti-D Drug Product in a parent clinical study.
排除标准
- •There are no exclusion criteria for this Study.
研究者
相似试验
招募中
3 期
ongterm Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug ProductCALDcerebral adrenoleukodystrophy10029299NL-OMON54368bluebird bio, Inc.3
进行中（未招募）
1 期
ongterm Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug ProductEUCTR2015-002805-13-DEbluebird bio, Inc67
进行中（未招募）
1 期
ongterm Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug ProductEUCTR2015-002805-13-NLbluebird bio, Inc60
进行中（未招募）
1 期
ongterm Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug ProductCerebral Adrenoleukodystrophy (CALD)MedDRA version: 20.0Level: PTClassification code 10051260Term: AdrenoleukodystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2015-002805-13-FRbluebird bio, Inc.25
进行中（未招募）
1 期
ongterm Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug ProductEUCTR2015-002805-13-GBbluebird bio, Inc60